Compare Marriott International Inc (MAR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Pfizer Inc — how do they compare? Marriott International Inc trades at $366.39 (market cap $96.76B), while Pfizer Inc trades at $24.83 (market cap $141.06B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.95%). Which is the better fit depends on your goals.
| MAR | PFE | |
|---|---|---|
Market Cap | $96.76B | $141.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $28.56 |
52-Week Low | $255.35 | $23.29 |
Enterprise Value | $113.71B | $191.72B |
Dividend Yield | 0.8% | 6.95% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $366.83, up 0.16% on the day, with technical indicators showing a bearish trend near key support at $364. The company reported Q1 2026 EPS of $2.72, beating expectations, and maintains a net income margin of 9.72% amid steady revenue growth. Recent developments include a strategic partnership with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook is mixed: analyst consensus targets $387.92 with 44% buy ratings, but rising debt-to-asset ratios and hotel owner disputes over the Bonvoy program pose risks. Earnings on August 3, 2026, will be critical for confirming growth trajectory amid competitive travel sector pressures.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
